Positron emission tomography and improved survival in patients with lung cancer: the Will Rogers phenomenon revisited.
暂无分享,去创建一个
D. Gandara | D. Nguyen | P. Lara | T. Wun | Monica Brown | K. Chee
[1] A. Jemal,et al. Cancer Statistics, 2008 , 2008, CA: a cancer journal for clinicians.
[2] S. Berlangieri,et al. Prevalence of occult metastatic disease in patients undergoing 18F‐FDG PET for primary diagnosis or staging of lung carcinoma and solitary pulmonary nodules , 2007, Internal medicine journal.
[3] T. Wasser,et al. Evidence for the will rogers phenomenon in migration of employees to managed care plans , 1999, Journal of General Internal Medicine.
[4] Robert Gray,et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. , 2006, The New England journal of medicine.
[5] B. Cheson,et al. Positron-emission tomography and assessment of cancer therapy. , 2006, The New England journal of medicine.
[6] J. Crowley,et al. Phase III trial of paclitaxel plus carboplatin with or without tirapazamine in advanced non-small-cell lung cancer: Southwest Oncology Group Trial S0003. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] Xin Li,et al. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] M. Socinski. Cytotoxic Chemotherapy in Advanced Non-Small Cell Lung Cancer , 2004, Clinical Cancer Research.
[9] Roy S Herbst,et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] W. Wright,et al. Socioeconomic status and breast cancer incidence in California for different race/ethnic groups , 2001, Cancer Causes & Control.
[11] B. Yalcin,et al. Multidisciplinary management of lung cancer. , 2004, The New England journal of medicine.
[12] J. Ornato,et al. Impact of the troponin standard on the prevalence of acute myocardial infarction. , 2003, American heart journal.
[13] P. Bunn. Chemotherapy for advanced non-small-cell lung cancer: who, what, when, why? , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] David Harrington,et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. , 2002, The New England journal of medicine.
[15] C. Compton,et al. AJCC Cancer Staging Manual , 2002, Springer New York.
[16] J. Crowley,et al. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non--small-cell lung cancer: a Southwest Oncology Group trial. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] Lori S. Parsons. Reducing Bias in a Propensity Score Matched-Pair Sample Using Greedy Matching Techniques , 2001 .
[18] H. Groen,et al. Preoperative staging of non-small-cell lung cancer with positron-emission tomography. , 2000, The New England journal of medicine.
[19] R. D'Agostino. Adjustment Methods: Propensity Score Methods for Bias Reduction in the Comparison of a Treatment to a Non‐Randomized Control Group , 2005 .
[20] A R Feinstein,et al. The Will Rogers phenomenon. Stage migration and new diagnostic techniques as a source of misleading statistics for survival in cancer. , 1985, The New England journal of medicine.
[21] D. Rubin,et al. The central role of the propensity score in observational studies for causal effects , 1983 .
[22] P. Trott,et al. International Classification of Diseases for Oncology , 1977 .
[23] W. Haenszel,et al. Statistical aspects of the analysis of data from retrospective studies of disease. , 1959, Journal of the National Cancer Institute.
[24] E. Kaplan,et al. Nonparametric Estimation from Incomplete Observations , 1958 .
[25] D.,et al. Regression Models and Life-Tables , 2022 .